Side effects of tirzepatide (Mounjaro): what you need to know
Short answer: The most common side effects of tirzepatide are nausea, diarrhoea and vomiting. These usually occur at the start of treatment, are temporary and subside after 4 to 8 weeks thanks to the gradual dosing schedule.
Mounjaro® (tirzepatide) is rapidly gaining ground as one of the most effective weight-loss medicines available today. The medicine acts on two receptors simultaneously: the GLP-1 receptor and the GIP receptor, resulting in greater weight loss than traditional GLP-1 medicines. However, it is precisely this dual action that raises legitimate questions about the side effects of tirzepatide. What can you expect? How long do the symptoms last? And when should you contact your doctor? In this blog post, you’ll find the answers.
What are the most common side effects of Mounjaro?
The most common side effects of Mounjaro are gastrointestinal symptoms: nausea, diarrhoea, vomiting, abdominal pain and constipation. These occur in a significant proportion of users, particularly during the first few weeks or following a dose increase. Reduced appetite is technically also a side effect, but is perceived by most users as desirable.
The SURMOUNT-1 study shows that nausea occurred in 28 to 39 per cent of participants, depending on the dose, whilst most cases were described as mild to moderate. Diarrhoea occurred in 17 to 23 per cent of participants. In most cases, these symptoms resolved on their own as the body became accustomed to the medication.
In addition, a slight increase in heart rate (3 to 5 beats per minute) has been reported. This is not usually clinically relevant, but should be taken into account in people with heart disease.
How long do the side effects of Mounjaro last?
Gastrointestinal side effects subside in most users after four to eight weeks. The dosing schedule for Mounjaro is specifically designed for this: treatment begins with 2.5 mg per week and is increased every four weeks to 5, 7.5, 10, 12.5 and finally a maximum of 15 mg per week, as described in the Pharmacotherapeutic Compass.
Safety data from a phase 3 study show that most side effects occurred during the first one to two dose increases and subsequently decreased significantly. The peak incidence of side effects is therefore at the start of treatment, not at the end.
Are there any serious side effects of tirzepatide?
Serious side effects do occur, but they are rare. The most relevant are acute pancreatitis, gallstones (cholelithiasis) and kidney problems resulting from dehydration due to persistent vomiting or diarrhoea. If you experience persistent severe abdominal pain radiating to the back, you should always contact a doctor.
In animal studies, thyroid cancer has been observed, a finding also reported with other GLP-1 medicines. This has not yet been demonstrated in humans, but tirzepatide is contraindicated for people with a personal or family history of medullary thyroid cancer. The same applies in cases of MEN2 (multiple endocrine neoplasia type 2).
Real-world studies show that serious side effects are rare with correct medical use and good follow-up. A thorough medical history at the start of treatment is therefore crucial.
How does Mounjaro differ from Ozempic and Wegovy in terms of side effects?
Tirzepatide acts on two receptors, GLP-1 and GIP, which means it is both more potent and qualitatively different from semaglutide (Ozempic/Wegovy). The side-effect profile is largely comparable, but at higher doses, gastrointestinal discomfort may be slightly more intense due to the stronger effect on gastric emptying.
A comparative study shows that tirzepatide in people with type 2 diabetes resulted in significantly greater weight loss than semaglutide 1 mg per week, with a comparable safety profile. Read more about the difference between Mounjaro and Ozempic or see the side effects of Ozempic for more information.
The table below summarises the key differences:
What can you do to reduce the side effects of Mounjaro?
The most effective way to limit side effects is to change your eating habits. Small, low-fat meals significantly reduce the risk of nausea. Avoid large portions, alcohol and foods high in fat or sugar, especially during the first few weeks after a dose increase. Good fluid balance is crucial, precisely because diarrhoea and vomiting can lead to dehydration.
Read more about diet when using GLP-1 for specific tips relevant to using Mounjaro. Some users experience fewer side effects if they administer the injection just before bedtime, so that the first few hours after the injection coincide with the night. The timing and choice of food together make a noticeable difference, particularly during the first four weeks of treatment. Goodweigh provides active support with each dose increase and adjusts the titration schedule if the side effects persist.
When should you stop taking Mounjaro due to side effects?
Stop using the medication and contact a doctor immediately if you experience severe, persistent abdominal pain, especially if it radiates to your back. This may indicate acute pancreatitis. Jaundice or dark urine may indicate liver problems or gallstones. Severe dehydration is characterised by dizziness, dark urine and reduced urine output.
Mild discomfort at the start is normal and expected. There is a difference between temporary discomfort when increasing the dose and symptoms that persist or worsen. If in doubt, contact your doctor. Medical guidance from Goodweigh is available throughout your treatment.
Side effects of Mounjaro are manageable with the right guidance
Most side effects of tirzepatide are mild, temporary and subside the longer you use the medicine. The dose escalation schedule, combined with changes in dietary habits, makes the treatment well tolerated by most people. The SURMOUNT-2 study shows that the side effect profile remains acceptable even with long-term use at higher doses.
Would you like to start taking Mounjaro safely under medical supervision? Through Goodweigh, you’ll undergo an online consultation, receive a personalised dosing schedule and have access to a team of doctors should you have any questions or concerns. Discreet home delivery, entirely online.
References
- Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., ... & Wadden, T.A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Frías, J.P., Davies, M.J., Rosenstock, J., Pérez Manghi, F.C., Fernández Landó, L., Bergman, B.K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://pubmed.ncbi.nlm.nih.gov/34170647/
- Garvey, W.T., Frias, J.P., Jastreboff, A.M., le Roux, C.W., Sattar, N., Aizenberg, D., ... & SURMOUNT-2 Investigators. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet, 402(10402), 613–626. https://pubmed.ncbi.nlm.nih.gov/37385275/
- Rosenstock, J., Wysham, C., Frías, J.P., Kaneko, S., Lee, C.J., Fernández Landó, L., ... & SURPASS-1 Investigators. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet, 398(10295), 143–155. https://pubmed.ncbi.nlm.nih.gov/34186022/
- Thomsen, R.W., Pedersen, L., Hasvold, P., Sandbæk, A., & García Rodríguez, L.A. (2025). Real-world evidence on GLP-1RA-based weight-loss therapies. Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/40196933/
- Farmacotherapeutisch Kompas. (2024). Tirzepatide. Zorginstituut Nederland. https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/t/tirzepatide
Your Final Weight Loss Program
Transform your life with our personalized telehealth weight loss program designed for lasting success.
.avif)
